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Monoarticular antigen-induced arthritis leads to pronounced
bilateral upregulation of the expression of neurokinin 1 and
bradykinin 2 receptors in dorsal root ganglion neurons of rats
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Statement of findings
This study describes the upregulation of neurokinin 1 and bradykinin 2 receptors in dorsal
root ganglion (DRG) neurons in the course of antigen-induced arthritis (AIA) in the rat knee.
In the acute phase of AIA, which was characterized by pronounced hyperalgesia, there was
a substantial bilateral increase in the proportion of lumbar DRG neurons that express
neurokinin 1 receptors (activated by substance P) and bradykinin 2 receptors. In the chronic
phase the upregulation of bradykinin 2 receptors persisted on the side of inflammation. The
increase in the receptor expression is relevant for the generation of acute and chronic
inflammatory pain.
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AIA = antigen-induced arthritis; B1 receptor = bradykinin 1 receptor; B2 receptor = bradykinin 2 receptor; BK = bradykinin; BSA = bovine serum
albumin; BCA-C = acetylated BSA; DMEM = Dulbecco’s modified Eagle’s medium; DRG = dorsal root ganglion; m-BSA = methylated bovine
serum albumin; NGF = nerve growth factor; NK1 = neurokinin 1; PBS = phosphate-buffered saline; SP = substance P.
Introduction: Ongoing pain and hyperalgesia (enhanced pain
response to stimulation of the tissue) are major symptoms of
arthritis. Arthritic pain results from the activation and
sensitization of primary afferent nociceptive nerve fibres (‘pain
fibres’) supplying the tissue (peripheral sensitization) and from
the activation and sensitization of nociceptive neurons in the
central nervous system (central sensitization). After
sensitization, nociceptive neurons respond more strongly to
mechanical and thermal stimulation of the tissue, and their
activation threshold is lowered. The activation and sensitization
of primary afferent fibres results from the action of inflammatory
mediators such as bradykinin (BK), prostaglandins and others
on membrane receptors located on these neurons. BK is a
potent pain-producing substance that is contained in
inflammatory exudates. Up to 50% of the primary afferent nerve
fibres have receptors for BK. When primary afferent nerve
fibres are activated they can release neuropeptides such as
substance P (SP) and calcitonin gene-related peptide from
their sensory endings in the tissue. SP contributes to the
inflammatory changes in the innervated tissue (neurogenic
inflammation), and it might also support the sensitization of
nociceptive nerve fibres by binding to neurokinin 1 (NK1)
receptors. NK1 receptors are normally expressed on a small
proportion of the primary afferent nerve fibres.
Aims: Because the expression of receptors on the primary
afferent neurons is essential for the pain-producing action of
inflammatory mediators and neuropeptides, we investigated in
the present study whether the expression of BK and NK1
receptors on primary afferent neurons is altered during the
acute and chronic phases of an antigen-induced arthritis (AIA).
AIA resembles in many aspects the inflammatory process of
human rheumatoid arthritis. Because peptide receptors are
expressed not only in the terminals of the primary afferent units
but also in the cell bodies, we removed dorsal root ganglia
(DRGs) of both sides from control rats and from rats with the
acute or chronic phase of AIA and determined, after short-term
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culture of the neurons, the proportion of DRG neurons that
expressed the receptors in the different phases of AIA. We also
characterized the inflammatory process and the nociceptive
behaviour of the rats in the course of AIA.
Materials and methods: In 33 female Lewis rats 10 weeks
old, AIA was induced in the right knee joint. First the rats were
immunized in two steps with methylated bovine serum albumin
(m-BSA) emulsified with Freund’s complete adjuvant, and heat-
inactivated  Bordetella pertussis. After immunization, m-BSA
was injected into the right knee joint cavity to induce arthritis.
The joint swelling was measured at regular intervals.
Nociceptive (pain) responses to mechanical stimulation of the
injected and the contralateral knee were monitored in the
course of AIA. Groups of rats were killed at different time
points after the induction of AIA, and inflammation and
destruction in the knee joint were graded by histological
examination. The DRGs of both sides were dissected from
segments L1–L5 and C1–C7 from arthritic rats, from eight
immunized rats without arthritis and from ten normal control
rats. Excised DRGs were dissociated into single cells which
were cultured for 18 h.
The expression of the receptors was determined by
assessment of the binding of SP–gold or BK–gold to the
cultured neurons. For this purpose the cells were slightly fixed.
Binding of SP–gold or BK–gold was detected by using
enhancement with silver and subsequent densitometric
analysis of the relative grey values of the neurons.
Displacement controls were performed with SP, the specific
NK1 receptor agonist [Sar9, Met(O2)11]-SP, BK, the specific
BK 1 (B1) receptor agonist D-Arg (Hyp3-Thi5,8-D-Phe7)-BK and
the specific BK 2 (B2) receptor agonist (Des-Arg10)-Lys-BK.
Results: The inflammatory process in the injected right knee
joint started on the first day after induction of AIA and persisted
throughout the observation period of 84 days (Fig. 1). The
initial phase of AIA was characterized by strong joint swelling
and a predominantly granulocytic infiltration of the synovial
membrane and the joint cavity (acute inflammatory changes). In
the later phases of AIA (10–84 days after induction of AIA) the
joint showed persistent swelling, and signs of chronic arthritic
alterations such as infiltration of mononuclear leucocytes,
hyperplasia of synovial lining layer (pannus formation) and
erosions of cartilage and bone were predominant. The
contralateral knee joints appeared normal at all time points.
Destruction was observed only in the injected knee but some
proteoglycan loss was also noted in the non-injected,
contralateral knee. In the acute and initial chronic phases of AIA
(1–29 days) the rats showed mechanical hyperalgesia in the
inflamed knee (limping, withdrawal response to gentle pressure
onto the knee). In the acute phase (up to 9 days) a pain
response was also seen when gentle pressure was applied to
the contralateral knee.
Figure 2 displays the changes in the receptor expression in the
DRG neurons during AIA. The expression of SP–gold-binding
sites in lumbar DRG neurons (Fig. 2a) was substantially
increased in the acute phase of arthritis. In untreated control
rats (n = 5), 7.7 ± 3.8% of the DRG neurons from the right side
and 10.0 ± 1.7% of the DRG neurons from the left side
showed labelling with SP–gold. The proportion of SP–gold-
labelled neurons in immunized animals without knee injection
(n = 3) was similar. By contrast, at days 1 (n = 2 rats) and 3
(n = 5 rats) of AIA in the right knee, approximately 50% of the
DRG neurons exhibited labelling with SP–gold, and this was
seen both on the side of the injected knee and on the opposite
side. At day 10 of AIA (n = 3 rats), 26.3 ± 6.1% of the
ipsilateral DRG neurons but only 15.7 ± 0.6% of the
contralateral neurons exhibited binding of SP–gold. At days 21
(n = 5 rats), 42 (n = 3 rats) and 84 (n = 5 rats) of AIA, the
Figure 1
Development of antigen-induced arthritis. (a) Diameters of the injected
knee joints and the contralateral knee joints at different time points of
arthritis. The contralateral knees show a slight increase in their
diameters owing to growth. (b–d) Arthritic changes of the knee joints
at 3, 10, 21, 42 and 84 days after the induction of arthritis, and of knee
joints from immunized non-arthritic animals (0 days) in comparison with
untreated normal control animals (n). (b) Histological examination of
acute inflammatory changes (fibrin exudation and granulocytic
infiltration of the synovial membrane and the joint cavity) in the injected
joint and the contralateral knee. (c) Histological examination of the
chronic inflammatory changes (hyperplasia of synovial lining, infiltration
of mononuclear leucocytes) of the injected joint and the contralateral
knee. (d) Overall joint destruction (pannus formation and erosion of
cartilage and bone) in the injected knee joint and in the contralateral
knee joint. (e) Loss of proteoglycans (staining with safranin O) in the
cartilage of the injected knee and the contralateral knee. All values are
means and standard deviations.
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proportion of SP–gold-positive neurons had returned to the
control values, although the arthritis, now with signs of chronic
inflammation, was still present. Compared with the DRG
neurons of the untreated control rats, the increase in the
proportion of labelled neurons was significant on both sides in
the acute phase (days 1 and 3) and the intermediate phase
(day 10) of AIA (Mann–Whitney U-test). The size distribution of
the neurons was similar in the DRG neurons of all experimental
groups. Under all conditions and at all time points, SP–gold
binding was found mainly in small and medium-sized (less than
700 mm2) neurons. In the cervical DRGs the expression of NK1
receptors did not change in the course of AIA. The binding of
SP–gold to the neurons was suppressed by the
coadministration of the specific NK1 receptor agonist [Sar9,
Met(O2)11]-SP in three experiments, showing that SP–gold
was bound to NK1 receptors.
The expression of BK–gold-binding sites in the lumbar DRG
neurons showed also changes in the course of AIA, but the
pattern was different (Fig. 2b). In untreated control rats (n = 5),
42.3 ± 3.1% of the DRG neurons of the right side and
39.6 ± 2.6% of the DRG neurons of the left side showed
binding of BK–gold. At days 1 (n = 2 rats) and 3 (n = 5 rats) of
AIA, approximately 80% of the DRG neurons on the side of the
knee injection (ipsilateral) and approximately 70% on the
opposite side were labelled. In comparison with the untreated
control group, the increase in the proportion of labelled neurons
was significant on both sides. The proportion of labelled
neurons in the ipsilateral DRGs remained significantly increased
in both the intermediate phase (day 10, n = 3 rats) and chronic
phase (days 21, n = 5 rats, and 42, n = 3 rats) of inflammation.
At 84 days after the induction of AIA (n = 5 rats), 51.0 ± 12.7%
of the neurons showed an expression of BK–gold-binding sites
and this was close to the prearthritic values. However, in the
contralateral DRG of the same animals the proportion of
BK–gold-labelled neurons declined in the intermediate phase
(day 10) and chronic phase (days 21–84) of AIA and was not
significantly different from the control value. Thus the increase in
BK–gold-labelled neurons was persistent on the side where the
inflammation had been induced, and transient on the opposite
side. The size distribution of the DRG neurons of the different
experimental groups was similar. In the cervical DRGs the
expression of BK receptors did not change in the course of AIA.
In another series of experiments, we determined the subtype(s)
of BK receptor(s) that were expressed in DRGs L1–L5 in
different experimental groups. In neither untreated control
animals (n = 5) nor immunized rats without knee injection
(n = 5) nor in rats at 3 days (n = 5) and 42 days (n = 5) of AIA
was the binding of BK–gold decreased by the coadministration
of BK–gold and the B1 agonist. By contrast, in these
experimental groups the binding of BK–gold was suppressed
by the coadministration of the B2 agonist. These results show
that B2 receptors, but not B1 receptors, were expressed in
both normal animals and in animals with AIA.
Discussion: These results show that in AIA in the rat the
expression of SP-binding and BK-binding sites in the perikarya
of DRGs L1–L5 is markedly upregulated in the course of knee
inflammation. Although the inflammation was induced on one
side only, the initial changes in the binding sites were found in
the lumbar DRGs of both sides. No upregulation of SP-binding
or BK-binding sites was observed in the cervical DRGs. The
expression of SP-binding sites was upregulated only in the first
days of AIA, that is, in the acute phase, in which the pain
responses to mechanical stimulation were most pronounced.
By contrast, the upregulation of BK-binding sites on the side of
AIA persisted for up to 42 days, that is, in the acute and
chronic phase of AIA. Only the B2 receptor, not the B1
receptor, was upregulated. The coincidence of the enhanced
expression of NK1 and BK receptors on sensory neurons and
the pain behaviour suggests that the upregulation of these
receptors is relevant for the generation and maintenance of
arthritic pain.
In the acute phase of AIA, approximately 50% of the lumbar
DRG neurons showed an expression of SP-binding sites.
Because peptide receptors are transported to the periphery,
the marked upregulation of SP-binding receptors probably
leads to an enhanced density of receptors in the sensory
endings of the primary afferent units. This will permit SP to
sensitize more neurons under inflammatory conditions than
under normal conditions. However, the expression of NK1
Figure 2
Bilateral upregulation of receptor expression during antigen-induced
arthritis. (a) Proportions of DRG neurons with binding of SP–gold in
control animals and in different groups of animals with AIA. (b)
Proportions of DRG neurons with binding of BK–gold in control
animals and in different groups of animals with AIA. Results for DRG
neurons from immunized animals without knee injection are shown at 0
days. White bars, contralateral to injected knee; black bars, ipsilateral
to injected knee.
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Introduction
Persistent pain is a major symptom of arthritis such as
human rheumatoid arthritis. Inflammatory pain is caused by
the activation and sensitization of primary afferent noci-
ceptive neurons (‘pain fibres’) supplying the tissue (periph-
eral sensitization), and from the activation and sensitization
of nociceptive neurons in the central nervous system
(central sensitization). After sensitization, nociceptive
neurons respond more strongly to mechanical and thermal
stimulation of the tissue, and their activation threshold is
lowered. These neuronal changes cause persistent pain
as well as hyperalgesia, an enhanced pain sensitivity to
mechanical and thermal stimuli [1–5]. The peripheral sen-
sitization is produced by the action of inflammatory media-
tors such as bradykinin (BK) and prostaglandins on the
primary afferent neurons that express receptors for these
compounds in their sensory endings [5,6]. Subgroups of
primary afferent neurons also express receptors for neu-
ropeptides such as substance P (SP) that are released
from primary afferent fibres.
Because the activation of primary afferent neurons by
mediators is dependent on the receptors located on the
neurons, we investigated in the present experiments the
expression of BK and SP [neurokinin 1 (NK1)] receptors
in primary afferent neurons in the acute and chronic
phases of antigen-induced arthritis (AIA), which resembles
in many aspects the inflammatory process of human
rheumatoid arthritis [7–10]. BK is a potent pain-producing
substance in animals and in humans. When it is applied to
the tissue it causes many neurons to fire action potentials,
and it sensitizes the neurons so that they respond more
strongly to mechanical and thermal stimuli [3,5,11–13].
BK is produced under inflammatory conditions from a pre-
cursor and is released in the plasma; it is contained in
inflammatory exudates, for example in the joint [14–17]. It
acts on BK 2 (B2) receptors that are expressed in sensory
neurons under normal conditions. Under inflammatory con-
ditions an additional expression of a BK 1 (B1) receptor
has been reported [6,18,19].
SP is a peptide that is produced in and released from the
primary afferent fibres themselves. Indeed, SP is synthe-
sized in 10–20% of the primary afferent neurons [20,21],
most of which seem to be nociceptive neurons with high
thresholds [22]. SP is transported from the cell bodies in
the dorsal root ganglia (DRGs) to the sensory endings in
the tissue, and the release from the sensory endings
causes a neurogenic inflammation [23–25]. SP is also
transported to the central terminals of the primary afferent
neurons. At this site it is involved in the activation and in
the generation of inflammation-evoked hyperexcitability of
spinal cord neurons [26–29]. SP acts on NK1 receptors
[30–33]. The application of SP to the tissue can sensitize
a proportion of the nociceptive primary afferent neurons,
suggesting that SP contributes to the generation of
hyperalgesia [34,35]. However, other studies have failed
to show effects of SP on primary afferent neurons
[36,37]. Thus, under normal conditions, the role of SP is
questionable.
Full article
receptors was upregulated only in the acute phase of
inflammation, suggesting that SP and NK1 receptors are less
important for the generation of hyperalgesia in the chronic
phase of AIA.
Because BK is one of the most potent algesic compounds, the
functional consequence of the upregulation of BK receptors is
likely to be of immediate importance for the generation and
maintenance of inflammatory pain. The persistence of the
upregulation of BK receptors on the side of inflammation
suggests that BK receptors should be an interesting target for
pain treatment in the acute and chronic phases. Only B2
receptors were identified in normal animals and in rats with AIA.
This is surprising because previous pharmacological studies
have provided evidence that, during inflammation, B1 receptors
can be newly expressed.
Receptor upregulation in the acute phase of AIA was bilateral
and almost symmetrical. However, hyperalgesia was much
more pronounced on the inflamed side. It is most likely that
receptors on the contralateral side were not readily activated
because in the absence of gross inflammation the local
concentration of the ligands BK and SP was probably quite
low. We hypothesize that the bilateral changes in receptor
expression are generated at least in part by mechanisms
involving the nervous system. Symmetrical segmental
changes can be produced only by the symmetrical
innervation, involving either the sympathetic nervous system
or the primary afferent fibres. Under inflammatory conditions,
primary afferent fibres can be antidromically activated
bilaterally in the entry zone of afferent fibres in the spinal
cord, and it was proposed that this antidromic activation
might release neuropeptides and thus contribute to
neurogenic inflammation. Because both sympathetic efferent
fibres and primary afferent nerve fibres can aggravate
inflammatory symptoms, it is also conceivable that they are
involved in the regulation of receptor expression in primary
afferent neurons. A neurogenic mechanism might also have
been responsible for the bilateral degradation of articular
cartilage in the present study.Because it is very difficult to study the expression of
peptide receptors in situ, we took advantage of the fact
that peptide receptors are expressed not only in the termi-
nals of the primary afferent units but also in the cell bodies
[33,38–40]. We therefore removed DRGs of both sides
from control rats and from rats with the acute or chronic
phase of AIA and determined, after short-term culture of
the neurons, the proportion of DRG neurons that
expressed the receptors under the different experimental
conditions. We also characterized the inflammatory
process and the nociceptive behaviour of the rats in the
course of AIA.
Materials and methods
Induction of joint inflammation
In 33 female Lewis rats 10 weeks old (Charles River,
Sulzfeld, Germany), an inflammation was induced in the
right knee joint. In the first step the rats received a subcu-
taneous injection of 500 mg of antigen [methylated bovine
serum albumin (m-BSA); Sigma, Deisenhofen, Germany]
in 500 ml of saline and emulsified with 500 ml of Freund’s
complete adjuvant [supplemented with 2 mg/ml Mycobac-
terium tuberculosis strain H37RA (Difco, Detroit, MI, USA]
and an intraperitoneal injection of 2 × 109 heat-inactivated
Bordetella pertussis (Pertussis-Referenzlabor, Kranken-
haus Berlin-Friedrichshain, Berlin, Germany). The same
immunization procedure was repeated seven days later.
After a further 14 days a sterile solution of antigen (m-
BSA) (500 mg in 50 ml of saline) was injected into the
cavity of the right knee joint (day 0). Eight animals received
the same immunization procedure excluding the injection
of antigen into the knee joint. The mediolateral diameters
of the knee joints were measured at regular intervals by
means of a vernier caliper (see Fig. 1a).
At 1, 3, 10, 21, 42 or 84 days after the induction of inflam-
mation in the knee joint, the rats were killed by cervical dis-
location during anaesthesia with ether. A total of 10
untreated rats of the same age and sex were used as
normal control animals. The immunized rats without arthri-
tis induction were killed 14 days after the second immu-
nization (day 0).
Two series of experiments were performed. In the first
series (n = 31 rats), we determined the expression of SP-
binding and BK-binding sites in the DRGs of lumbar seg-
ments L1–L5. The nerves innervating the knee joint are
contained in these segments. In the second series of
experiments (n = 20 rats) we again took DRGs from seg-
ments L1–L5 to determine the BK receptor subtypes, and
we removed DRGs from cervical segments C1–C7 to
determine the expression of NK1 and BK receptors in the
primary afferent neurons at the cervical level. In addition, a
detailed documentation of the behaviour was performed in
the second series. All procedures complied with the regu-
lations of the Thuringian Commission for Animal Protection.
Histology and grading of arthritis
After the rats had been killed, both knee joints were
removed, skinned, fixed in 4% buffered formalin, decalci-
fied in EDTA, embedded in paraffin, cut into 5 mm frontal
sections and stained with haematoxylin–eosin for micro-
scopic examination. Three sections per knee joint were
examined in a blind fashion by two independent observers
(PKP and RB) with the use of a semiquantitative score (0 =
no, 1 = mild, 2 = moderate, 3 = severe alterations). The
acute inflammatory reaction was assessed by evaluating
the quantity of fibrin exudation and the relative number and
density of granulocytes in the synovial membrane and in
the joint space. The chronic inflammatory reaction was
quantified on the basis of the relative number and density
of infiltrating mononuclear leucocytes in the synovial mem-
brane, the degree of synovial hyperplasia, and the extent of
fibrosis in the synovial tissues. The histological score is the
sum of the three parameters evaluated. A score from 0 to 4
was used to assess the degree of cartilage destruction: 0,
no destruction; 1, unequivocal erosions of less than 10%
of cartilage and bone cross sections; 2, erosion of
10–25%; 3, erosion of 25–50%; 4, erosion of more than
50% of cartilage and bone cross sections. Additional sec-
tions were stained with safranin O to determine the loss of
proteoglycan in the cartilage matrix, with the use of the
same score as for the evaluation of inflammatory reactions.
Testing of nociceptive behaviour
At several time points after the induction of AIA, the
behaviour of rats (at least n = 5 rats for each time point)
was assessed by using a score. First each rat was placed
in a box in which it could move freely. The severity of dis-
turbances of walking was graded: 4, no walking; 3,
walking on three legs; 2, limping with the leg with inflam-
mation; 1, limping with the leg with inflamed knee only
after pressure on the knee; 0, normal walking. Other para-
meters (exploratory behaviour, standing on hindlimbs)
were also checked and documented. Thereafter the rats
were held in the hand by one experimenter and the follow-
ing tests were performed by the other experimenter:
flexion/extension of the left and right knee joint as well as
an application of moderate non-painful and strong, lightly
painful pressure onto the ankle joints and the knee joints.
In all these cases we determined whether the rat showed
a nociceptive reaction, namely a withdrawal of the stimu-
lated leg. By using a mechanical device that applied pres-
sure to a small area, we administered pressure to the
lateral side of the knee joint and determined the pressure
range at which the rat withdrew the leg. Responses to
pressure in the range 0–100 g were scored 3 (this stimu-
lus evokes a touch sensation in humans), responses to
pressure in the range 100–200 g were scored 2 (this
stimulus evokes a pressure sensation), responses to
200–250 g were scored 1 and a lack of response to
250 g was scored 0 (the application of 250 g evokes a
weak pain sensation). For analysis, the scores of all
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tested in the group.
Preparation of the DRGs
Because the fixation of the animals by perfusion impairs
the binding of gold-labelled peptides and because the
structure of DRGs in cryostat sections is not well main-
tained, we removed the DRGs after killing the animals and
put the neurons into short-term culture. The DRGs of both
sides were dissected quickly from segments L1–L5 or
from segments C1–C7. The ganglia were incubated at
37°C in 0.28 U/ml collagenase type A (Boehringer,
Mannheim, Germany) dissolved in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco BRL, Eggenstein,
Germany) for 100 min. After being washed with phos-
phate-buffered saline (PBS, 20 mmol, pH 7.4), the ganglia
were incubated in PBS containing 25,000 U/ml trypsin
(Sigma) for 11 min at 37°C. Then the ganglia were disso-
ciated into single cells by gentle agitation and by tritura-
tion through a fire-polished Pasteur pipette. The cells were
washed three times in DMEM by centrifugation (500 g,
5 min). The final cell pellet was suspended in Ham’s F-12
medium (Gibco BRL) containing 10% heat-inactivated
horse serum (Gibco BRL), 100 U/ml penicillin (Gibco
BRL), 100 mg/ml streptomycin (Gibco BRL) and
100 ng/ml nerve growth factor (7S, recombinant human;
Boehringer). Cells were plated on 13 mm glass coverslips
coated with poly-(L-lysine) (200 mg/ml) and kept for 18 h
at 37°C in a humidified incubator gassed with 3.5% CO2
in air. Cells were fed after 14–16 h with supplemented
Ham’s F-12 medium (see above).
Preparation of the SP–gold and BK–gold conjugates
SP (Sigma) (1 mmol) or 1 mmol of BK (Bachem, Heidel-
berg, Germany) was dissolved in 500 ml of HEPES
(20 mmol, pH 7.5). This solution was added to 6 nmol of
sulpho-N-hydroxysuccinimido Nanogold reagent (BioTrend,
Köln, Germany), dissolved in 500 ml of doubly distilled
water and incubated for 1 h at room temperature. To sepa-
rate SP–gold or BK–gold conjugates from unbound SP or
BK, membrane centrifugation (Amicon Microcon-10
system) was used. The SP–gold and BK–gold conjugates
were dissolved in PBS containing 0.1% bovine serum
albumin (BSA), 0.2 mol of sucrose, 4 mg/ml leupeptin and
10 mmol of sodium azide. This solution was aliquoted and
stored at –20°C for a maximum of 3 months.
SP–gold and BK–gold binding to cultured neurons
The cells were pre-fixed with 2% paraformaldehyde and
0.05% glutaraldehyde in 0.1 mol of phosphate buffer (pH
7.2) for 30 min. After being washed with PBS (20 mmol,
pH 7.4), the cells were pretreated with 50 mmol of glycine
in PBS and thereafter with 5% BSA and 0.1% gelatine in
PBS for 30 min. The cells were then washed with 0.1%
acetylated BSA (BSA-C) and incubated overnight with 0.3
nmol/ml SP–gold in PBS or with 0.3 nmol/ml BK–gold
containing 0.1% BSA-C, bacitracin (40 mg/ml), leupeptin
(4 mg/ml) and chymostatin (2 mg/ml) at 4°C in a moist
chamber. After being washed with PBS plus 0.1% BSA-C
and thereafter with PBS to remove unbound SP–gold or
BK–gold, cells were postfixed with 2% glutaraldehyde in
PBS for 10 min. After extensive washing with PBS and
doubly distilled water, the gold particles were intensified
with silver enhancer (R-Gent, pH 5.5; BioTrend) for
15 min at 22°C. The reaction was stopped by washing in
doubly distilled water. The preparations were dehydrated
and embedded in DePeX (Fluka, Neu-Ulm, Germany).
Control incubations
To determine the specificity of the SP–gold or BK–gold
complex used in the binding studies, a displacement
control was performed. Neurons were incubated in
1 mmol/ml unlabelled SP or 1 mmol/ml unlabelled BK
together with 0.3 nmol/ml peptide–gold. The unlabelled
peptides should decrease or prevent binding of the gold-
labelled peptides. Furthermore, to test whether SP–gold is
bound specifically to NK1 receptors, 0.3 nmol/ml SP–gold
was incubated in the presence of 1 mmol/ml  [Sar9,
Met(O2)11]-SP (Bachem), a specific agonist at the NK1
receptor. To examine whether the binding of BK–gold is
related to BK receptors, 0.3 nmol/ml BK–gold was incu-
bated in the presence of 1 mmol/ml of D-Arg (Hyp3-Thi5,8-
D-Phe7)-BK, a BK analogue specific for the B1 receptor
(Bachem), and/or 1 mmol/ml of (Des-Arg10)-Lys-BK, a B2
receptor agonist (Bachem).
Data analysis
At different time points after induction of inflammation, DRG
preparations of two to five rats were used to determine
SP–gold-binding and BK–gold-binding sites. The DRGs of
untreated rats served as the control group. DRGs were also
removed from immunized but non-arthritic animals (day 0
group). To analyse the data, from every coverslip 50 or 100
structurally intact neurons were examined with a light micro-
scope (Zeiss; Axiophot, Jena, Germany) coupled to a CCD
colour video camera [AVT-BC6(0)] and an image-analysing
system (Kontron, Eching, Germany). On each coverslip,
neurons were randomly selected; neurons obstructed by
other neurons or by tissue were not included. In total
30500 neurons were analysed. The relative grey value (grey
value of the soma/grey value of the substrate background)
was determined for each soma. From each individual
binding experiment one coverslip was used to perform a
displacement control incubation (see above). This allowed
us to determine the grey value range of neurons with no
SP–gold or no BK–gold binding in each experiment (see
Fig. 5, white bars). In all other coverslips of the particular
experiment, neurons were considered as positive for
peptide-binding sites if they had a relative grey value above
that of neurons from the control incubation. For the final
analysis, data from the experiments were pooled. Group
results are expressed as means and standard deviations. To
http://arthritis-research.com/content/2/5/424evaluate the cell size, the cross-sectional area was taken
from each selected neuron. For statistical evaluation, four
groups of DRGs were formed, namely DRGs of untreated
control rats, of the acute phase (1 and 3 days), of the
chronic phase (21 and 42 days) and of the intermittent
phase (10 days) of AIA. For comparison of the AIA groups
with the control group the Mann–Whitney U-test was used,
with adjustment of significance values for multiple compar-
isons; significance was accepted at P < 0.05 [41].
Results
Joint inflammation
Figure 1 shows the time course of the inflammatory
process. The swelling of the injected knee is shown in
Fig. 1a (dots). The diameter of the contralateral knees
showed a slight increase over time owing to growth. The
time course of acute inflammatory changes (a predomi-
nantly granulocytic infiltration of the synovial membrane
and the joint cavity) is shown in Fig. 1b; the time course of
chronic alterations (infiltration of mononuclear leucocytes,
hyperplasia of synovial lining layer, extent of fibrosis) is dis-
played in Fig. 1c. The contralateral knee joints seemed
normal at all time points. Figure 1d summarizes the
destruction of the joints, taking into account the erosion of
cartilage and bone and the formation of synovial pannus.
Figure 1e depicts the depletion of cartilage proteoglycan
(evidenced by the loss of staining with safranin O).
Although destruction was observed only in the injected
knee, some proteoglycan loss was also noted in the non-
injected, contralateral knee.
Nociceptive behaviour (pain response)
At 1–29 days after the induction of AIA, the rats showed
signs of mechanical hyperalgesia in the leg with inflamma-
tion. Most striking were the disturbances of gait (Fig. 3a).
At 1–3 days most rats did not use the leg with inflamma-
tion for walking. At 9–21 days of AIA, the rats showed
marked limping of the leg with the injected knee. At 29
days of AIA, limping was seen only after the knee had
been pressed. Normal gait was observed after 37 days of
AIA. Furthermore, at 1–9 days of AIA, rats did not stand
on the hindfeet or visibly loaded only the foot of the leg
with the non-injected knee. Exploring behaviour fell from
day 2 to day 9 of AIA. When the inflamed knee was manu-
ally flexed and extended, the rats showed an immediate
defence reaction at 1–9 days of AIA. Movements of the
contralateral knee did not elicit defence behaviour. Local
pressure onto the injected and non-injected knee revealed
that the local threshold in the injected knee was markedly
reduced at 1–9 days of AIA but a reduction was also seen
on the contralateral side (Fig. 3b). Between 14 and 29
days of AIA, the rats showed a withdrawal response when
the injected knee was compressed between two fingers
with moderate intensity, whereas strong and painful com-
pression was necessary to evoke a withdrawal response
to pressure on the contralateral knee.
Expression of SP–gold- and BK–gold-binding sites in DRGs
from control and arthritic rats
Figure 4 shows neurons that were isolated from DRGs
L1–L5 3 days after the induction of AIA and then cultured.
Neurons labelled with SP–gold (Fig. 4a) or with BK–gold
(Fig. 4b) appear dark as a result of the silver staining of
the gold particles (arrows). The next sections will illustrate
the data analysis and summarize the data on the receptor
expression.
SP–gold binding sites
Lumbar DRGs
Figure 5 exemplifies the data analysis. In the DRGs of both
sides of all animals, control incubations were performed in
which SP was administered in excess together with
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Figure 3
Nociceptive behaviour of the rats in different experimental groups. (a)
Description of the gait, scored as follows: 4, no walking; 3, walking on
three legs; 2, limping with the injected leg; 1, limping after pressure on
the knee; 0, normal walking. (b) Withdrawal response of the injected
and the contralateral knee on local stimulation of the knee with a
mechanical device, scored as follows: 3, response to pressure in the
range 75–150 g; 2, response to pressure in the range 150–200 g; 1,
response to pressure in the range 200–250 g; 0, no response to
pressure of more than 250 g. The symbols show mean scores and
standard deviations. In (a) the standard deviation was zero at most
time points.
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after induction of AIASP–gold, to suppress the binding of SP–gold. Figure 5a
displays the distribution of the grey values of neurons of
the DRGs of both sides from these control incubations.
The grey values were in the range 0.0–0.16 (white bars),
and thus this range of grey values does not indicate
labelling with SP–gold. In all other incubations only
SP–gold was used. In the DRGs of healthy untreated
control animals (n = 5) approximately 9% of the DRG
neurons of both sides exhibited grey values of more than
0.16 (black bars), indicating binding of SP–gold (Fig. 5b).
Similar findings were obtained in DRG neurons from
immunized non-arthritic rats (n = 3; Fig. 5c). By contrast,
in DRG from rats (n = 5) in which the inflammation had
been induced on the ipsilateral side three days previously,
a much higher proportion of DRG neurons of both sides
exhibited grey values of more than 0.16, indicating binding
of SP–gold (Fig. 5d). These inflammation-induced
changes were reversible (Fig. 5e).
Figure 2a displays the proportions of DRG neurons that
showed binding of SP–gold in the different groups of
rats. In the untreated control rats (n = 5), 7.7 ± 3.8% of
the DRG neurons from the right side (black bars) and
10.0 ± 1.7% of the DRG neurons from the left side (white
bars) showed labelling with SP–gold. The proportion of
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Figure 4
Isolated DRG neurons of the adult rat after incubation with SP–gold
(a) or BK–gold (b) and subsequent enhancement with silver. The
neurons were cultured for 18 h. The black staining indicates binding of
SP–gold or BK–gold (arrows).
Figure 5
Distribution of the relative grey values of DRG neurons ipsilateral and
contralateral to the injected knee with SP–gold binding. (a) Neurons
(n = 800, from eight cultures) from control incubations treated with an
excess of substance P that was administered together with SP–gold.
(b) Neurons (n = 500, from five cultures) from untreated control
animals. (c) Neurons (n = 300, from three cultures) from immunized
animals without knee injection. (d) Neurons (n = 500, from five
cultures) from rats 3 days after the induction of arthritis (3 days). (e)
Neurons (n = 500, from five cultures) from AIA rats (21 days). White
bars, neurons exhibiting grey densities that were in the range of those
observed in neurons from control incubations; black bars, neurons
exhibiting grey densities that were higher than those observed in the
neurons from control incubations.
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relative grey valueSP–gold-labelled neurons in immunized animals without
knee injection (n = 3) was similar. By contrast, at days 1
(n = 2 rats) and 3 (n = 5 rats) of AIA in the right knee,
approximately 50% of the DRG neurons exhibited
labelling with SP–gold, and this was seen both on the
side of the injected knee and on the opposite side. At day
10 of AIA (n = 3 rats), 26.3 ± 6.1% of the ipsilateral DRG
neurons but only 15.7 ± 0.6% of the contralateral
neurons exhibited binding of SP–gold. At days 21 (n =5
rats), 42 (n = 3 rats) and 84 (n = 5 rats) of AIA, the pro-
portion of SP–gold-positive neurons had returned to the
control values, although the inflammation was still
present. In comparison with the DRG neurons of the
untreated control rats, the increase in the proportion of
labelled neurons was significant on both sides in the
acute phase (days 1 and 3) and the intermediate phase
(day 10) of AIA (Mann–Whitney U-test). The size distribu-
tion of the neurons was similar in the DRG neurons of all
experimental groups. The white bars in Figure 6 show the
distribution of the areas of all neurons measured, and the
black insets show the subset of neurons with SP–gold-
binding sites. Under all conditions and at all time points,
SP–gold binding was found mainly in small and medium-
sized (less than 700 mm2) neurons.
To show that SP–gold was bound to NK1 receptors we
tried to suppress the binding of SP–gold to the neurons
by the specific NK1 agonist [Sar9, Met(O2)11]-SP in three
experiments. In Fig. 7 the histograms on the left side show
the grey density of the neurons from two experimental
groups treated only with SP–gold. A proportion of these
neurons exhibited grey values of more than 0.16, indicat-
ing binding of SP–gold. The histograms on the right side
show that neurons with grey values of more than 0.16
were not found when SP–gold was administered together
with the specific NK1 receptor agonist. Thus SP–gold
specifically labelled NK1 receptors.
Cervical DRGs
In the cervical DRGs the expression of NK1 receptors did
not change in the course of AIA (Table 1). NK1 receptors
were expressed in approximately 10% of the neurons in
untreated control animals (n = 5), in immunized animals
without knee injection (n = 5), in rats at 3 days of AIA in the
knee (n = 5), and in 5 rats at 42 days of AIA in the knee.
BK–gold-binding sites
Lumbar DRGs
Figure 8 shows the distribution of grey values in neurons
in which labelling with BK–gold was used. Figure 8a dis-
plays the grey values from neurons of all control incuba-
tions with BK–gold and BK. The other graphs show
specific BK–gold-binding sites (grey values of more than
0.16) in neurons from untreated control animals (Fig. 8b),
from immunized rats without knee injection (Fig. 8c) and
from rats with AIA (Fig. 8d and e).
Figure 2b shows the proportions of neurons with binding
of BK–gold in the different groups of rats. In untreated
control rats (n = 5), 42.3 ± 3.1% of the DRG neurons of
the right side (black bars) and 39.6 ± 2.6% of the DRG
neurons of the left side (white bars) showed binding of
BK–gold. At days 1 (n = 2 rats) and 3 (n = 5 rats) of AIA,
approximately 80% of the DRG neurons on the side of the
knee injection (ipsilateral) and approximately 70% on the
opposite side were labelled. In comparison with the
untreated control group the increase in the proportion of
labelled neurons was significant on both sides. The pro-
portion of labelled neurons in the ipsilateral DRGs
remained significantly increased in both the intermediate
phase (day 10, n = 3 rats) and chronic phase (days 21,
n = 5 rats, and 42, n = 3 rats) of inflammation. At 84 days
after the induction of AIA, 51.0 ± 12.7% of the neurons
showed an expression of BK–gold-binding sites and this
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Figure 6
Size distribution of the cultured neurons from different experimental
groups. The white bars show the proportions of neurons with different
areas from experiments in which SP–gold-binding sites were
determined. The neurons with SP–gold-binding sites are shown by the
black bars.
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]was close to the prearthritic values. In the contralateral
DRG of the same animals, however, the proportion of
BK–gold-labelled neurons declined in the intermediate
phase (day 10) and chronic phase (days 21–84) of AIA
and was not significantly different from the control value.
Thus the increase in BK–gold-labelled neurons was per-
sistent on the side where the inflammation had been
induced, and transient on the opposite side.
The size distributions of the DRG neurons of the different
experimental groups were similar (Fig. 9). Under all condi-
tions and at all time points, BK–gold binding was found
mainly in small and medium-sized neurons. The binding of
BK–gold in these experiments was suppressed by the
administration of a mixture of both the B1 and B2 agonists
(data not shown).
In another series of experiments, we made an effort to
determine the subtype(s) of BK receptor(s) that were
expressed in DRGs L1–L5 in different experimental
groups. The data are displayed in Table 2. In neither
untreated control animals (n = 5) nor immunized rats
without knee injection (n = 5) nor rats at 3 days (n =5 )
and 42 days (n = 5) of AIA was the binding of BK–gold
reduced by the coadministration of BK–gold and the B1
agonist. By contrast, in these experimental groups the
binding of BK–gold was suppressed by the coadministra-
tion of the B2 agonist. These data show that in both
normal animals and animals with AIA, B2 receptors but not
B1 receptors were expressed.
Cervical DRGs
In the cervical DRGs the expression of BK receptors did
not change in the course of AIA (Table 1). BK receptors
were expressed in approximately 40% of the neurons in
untreated control animals (n = 5), in immunized animals
without knee injection (n = 5), in rats at 3 days of AIA in the
knee (n = 5), and in 5 rats at 42 days of AIA in the knee.
Discussion
These results show that the expression of SP-binding and
BK-binding sites in the perikarya of DRGs L1–L5 is
markedly upregulated in the course of inflammation in the
knee joint. Several aspects are noteworthy. Firstly,
although the inflammation was induced on one side only,
the initial changes in the binding sites were found in the
lumbar DRGs of both sides. No upregulation of SP-
binding and BK-binding sites was observed in the cervi-
cal DRGs. Secondly, whereas the expression of
SP-binding sites was upregulated only in the first days of
AIA, that is, in the acute phase, the upregulation of BK-
binding sites on the side of AIA persisted for up to 42
days. Thirdly, and unexpectedly, only the B2 receptor, not
the B1 receptor, was upregulated. The enhanced expres-
sion of NK1 and BK receptors on sensory neurons might
be an important mechanism by which arthritis causes
pain and hyperalgesia.
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Figure 7
Displacement control for SP–gold with the specific NK1 receptor
agonist [Sar9, Met(O2)11]-SP in DRG neurons ipsilateral and
contralateral to the injected knee. The histograms on the left show the
distribution of the grey values after treatment with SP–gold; the
histograms on the right show the distribution of the grey values after
the administration of SP–gold and [Sar9, Met(O2)11]-SP (1 mmol/ml)
together.
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Table 1
Expression of neurokinin 1 and bradykinin receptors in cervical
DRGs ipsilateral to the inflamed knee joint
Percentage of neurons with:
SP–gold- BK–gold-
Experimental group binding sites binding sites
Untreated control animals 10.4 ± 2.2 39.2 ± 3.9
Immunized rats without knee injection 11.6 ± 0.9 38.4 ± 4.3
AIA 3 days 10.2 ± 1.9 42.0 ± 3.2
AIA 42 days 8.4 ± 3.6 42.8 ± 4.4
Values shown are the means and standard deviations.Inflammation and nociceptive behaviour
The limping during walking and the withdrawal responses
to pressure on the joint show that the rats experienced pain
during mechanical stimulation of the inflamed joint
(mechanical hyperalgesia). Mechanical hyperalgesia is also
a leading symptom of human arthritis, and thus AIA in the
rat seems to be a suitable model for studying the mecha-
nisms of arthritic pain. Hyperalgesia was most marked in
the acute phase and less severe when the acute phase
subsided. Interestingly, later stages of AIA were not obvi-
ously painful although the chronic inflammation and joint
destruction persisted. Although hyperalgesia was pro-
nounced in the knee with inflammation, signs of weak
hyperalgesia were also noted on the contralateral side at
1–9 days of AIA because the mechanical thresholds were
lowered. However, the pain response was quite asymmetri-
cal; the main symptoms were on the injected side.
Methodological considerations for the use of DRG
During inflammation, pain is elicited by the activation and
sensitization of the sensory endings of nociceptors in the
tissue. For technical reasons it is currently impossible to
study molecular nociceptive processing and quantitative
changes in receptor expression in the sensory endings in
situ. However, the cell body of DRG neurons is thought to
serve as a valid model for the sensory endings, for three
reasons:
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Figure 8
Distribution of the relative grey values of DRG neurons ipsilateral and
contralateral to the injected knee with BK–gold binding. (a) Neurons
(n = 800, from eight cultures) from control incubations treated with an
excess of BK that was administered together with BK–gold. (b)
Neurons (n = 500, from five cultures) from untreated control animals.
(c) Neurons (n = 300, from three cultures) from immunized animals
without knee injection. (d) Neurons (n = 500, from five cultures) from
AIA rats (3 days). (e) Neurons (n = 300, from three cultures) from AIA
rats (42 days). White bars, neurons exhibiting grey densities that were
in the range of those observed in neurons from control incubations;
black bars, neurons exhibiting grey densities that were higher than
those observed in the neurons from control incubations.
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Figure 9
Size distribution of the cultured neurons from different experimental
groups. The white bars show the proportions of neurons with different
areas from experiments in which BK–gold-binding sites were
determined. The neurons with BK–gold-binding sites are shown by the
black bars.
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ipsilateral contralateral1. The perikarya of DRG neurons express ion channels
that seem also to be present in the sensory endings,
for example ion channels that are activated by noxious
heat and other noxious stimuli [42,43].
2. The perikarya of DRG neurons express receptors for
ligands that activate the sensory endings in prepara-
tions in vivo and in vitro, for example capsaicin and BK
[11,44–47].
3. Mediators can be released from the perikarya that are
usually released from the sensory and spinal endings
of the primary afferent fibres [48–50].
We therefore believe that the receptor expression in the
cell bodies of DRG neurons also represents the receptor
expression in the sensory terminals of the DRG neurons.
DRG neurons were cultured for 18 h after they had been
removed from the rats. In the process of culturing,
neurons might be lost, and cultured neurons might show
changes compared with neurons in situ; this could influ-
ence the basal expression of receptors, for example.
However, the neurons from different experimental groups
were cultured in the same way, and the distribution of the
cell sizes was similar in all preparations. Therefore
changes in the expression of binding sites are most prob-
ably the outcome of pathophysiological changes in the rat
during the inflammation.
Expression and upregulation of SP-binding sites during
inflammation
Evidence was provided that some primary afferent neurons
express receptors for SP. Low levels of NK1 receptor
mRNA were identified in DRG of the mouse [30]. Immuno-
histochemical staining of NK1 receptors has been found in
a proportion of unmyelinated axons of rat glabrous skin in
situ [31]. In cultured DRG neurons, 10–20% of the
perikarya show binding of SP–gold. Binding of SP–gold
can be suppressed by the coadministration of a specific
NK1 receptor agonist but not of specific NK2 and NK3
receptor agonists [33]. A similar proportion of cultured
DRG neurons show binding of an antibody directed
against the carboxy terminus of the NK1 receptor (unpub-
lished data). The application of SP to freshly isolated DRG
neurons evokes an inward current [32], and changes in
intracellular Ca2+ concentration were seen after the appli-
cation of SP or NK1 agonists to cultured DRG neurons
[51]. However, other studies failed to identify NK1 recep-
tors in primary afferent neurons [52–54]. Thus the expres-
sion of functional NK1 receptors in the perikarya of DRG
neurons is not entirely settled [55]. There is still debate on
whether or not the effect of SP on sensory endings is
important for the generation of pain (see below).
During inflammation in the periphery, the synthesis of SP
in DRGs is upregulated [56–63]. More SP is released
from the sensory endings in the periphery (producing for
example neurogenic inflammation) and from the synaptic
endings in the spinal cord [26]. An upregulation of NK1
receptors during inflammation has been observed in spinal
cord neurons [64–67]. Here we show that there is also a
marked upregulation of SP-binding sites in primary affer-
ent neurons. The low proportion of neurons with SP-
binding sites in the normal animal (approximately
10–20%) could be the reason why SP was found to affect
primary afferent neurons in some studies [34,35] but not
in others [36,37]. In the acute phase of AIA, approximately
50% of the lumbar DRG neurons showed an expression
of SP-binding sites. Because the binding of SP–gold can
be suppressed by a specific NK1 receptor agonist (this
study) but not by specific agonists at the NK2 and NK3
receptor [33], we believe that the SP–gold-binding sites
represent NK1 receptors.
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Table 2
Expression of bradykinin 1 and bradykinin 2 receptors in DRGs L1–L5
Percentage of labelled neurons
Experimental group Test site BK–gold BK–gold + BK1 agonist BK–gold + BK2 agonist
Untreated control animals i.l. 38.8 ± 7.0 38.0 ± 2.4 0
c.l. 40.4 ± 0.9 41.6 ± 4.6 1.2 ± 1.8
Immunized rats without knee injection i.l. 42.0 ± 1.4 38.8 ± 2.3 0
c.l. 41.6 ± 5.2 38.8 ± 6.1 0
Rats at 3 days of AIA i.l. 77.0 ± 3.4 83.4 ± 2.9 0.4 ± 0.9
c.l. 88.0 ± 4.7 88.0 ± 4.7 1.6 ± 2.1
Rats at 42 days of AIA i.l. 74.8 ± 4.8 71.6 ± 8.9 0.4 ± 0.9
c.l. 38.8 ± 2.3 38.0 ± 2.5 1.6 ± 3.6
Values shown are the means and standard deviations. Abbreviations: i.l., ipsilateral to injected knee; c.l., contralateral to injected knee.Because peptide receptors are transported to the periph-
ery, the marked upregulation of SP-binding receptors prob-
ably leads to an enhanced density of receptors in the
sensory endings of the primary afferent units. This allows SP
to sensitize more neurons under inflammatory conditions
than under normal conditions. It is therefore likely that the
upregulation of NK1 receptors contributes to hyperalgesia
during arthritis. Indeed, the upregulation of NK1 receptors
coincided with the marked pain responses that were seen in
the acute phase of inflammation. However, the final proof of
the involvement of NK1 receptors in the arthritic pain will
require additional functional experiments. In the chronic
phase NK1 receptors seem to be less important.
Expression and upregulation of BK-binding sites during
inflammation
As shown by several methods, primary afferent neurons
express BK receptors in their perikarya in the DRGs and
also in their peripheral sensory and spinal synaptic
endings [11,38–40,67,68]. Although the functional
effects of SP on nociceptive afferent neurons are still
under discussion (see the last paragraph), there is full
agreement that BK causes pain in animals and humans. In
the present study, DRGs from AIA rats exhibited more
neurons with BK-binding sites. Thus, during AIA more
primary afferent neurons can be activated and sensitized
by the inflammatory mediator BK, and thus the upregula-
tion of the BK-binding sites is likely to be an important
mechanism by which arthritis causes severe pain.
Because the increased expression of BK-binding sites
persisted for up to 42 days on the side of inflammation,
BK-binding sites should be an interesting target for pain
treatment in the acute and chronic phases of arthritis.
Only the specific B2 agonist, not the specific B1 agonist,
suppressed the binding of BK–gold, suggesting that the
BK receptors in the DRG in the present study were B2
receptors. This is surprising because previous pharmaco-
logical studies have provided evidence that, during inflam-
mation, B1 receptors are newly expressed [6,18,19]. It is
unlikely that the specific B1 agonist did not work in the
present experiments for technical reasons, because this
B1 agonist reduced the binding of BK–gold in another
study with the same technique [68]. Indeed, when BK
receptors are upregulated after nerve lesion, a bilateral
increase in BK receptors involves the upregulation of B2
receptors and an expression of B1 receptors de novo
[68]. We therefore conclude that the increased expres-
sion of BK receptors in AIA is entirely due to an upregula-
tion of the B2 receptor.
Bilateral effects and possible mechanisms of upregulation
of receptors
Receptor upregulation in the acute phase of AIA was bilat-
eral and almost symmetrical. However, the hyperalgesia
was much more pronounced on the inflamed side. That
the pain responses were asymmetrical in spite of a sym-
metrical receptor upregulation is most probably due to the
fact that the receptors on the contralateral side were not
readily activated because in the absence of gross inflam-
mation the local concentration of the ligands BK and SP
was probably quite low.
At present it is unclear which mechanisms cause the
upregulation of BK-binding and SP-binding sites. Because
the expression of BK receptors in cultured DRG neurons
can be regulated, for example by nerve growth factor
(NGF) [39], we assume that mediators of different sources
(such as immune cells and nerve cells) could have a role.
NGF could be a candidate because inflamed tissue shows
a rapid enhancement of NGF [69–71]. NGF can also regu-
late the synthesis of neuropeptides such as SP [72,73].
Although such mechanisms could explain the upregulation
of receptors on the side of inflammation, it is intriguing to
consider which mechanisms are possibly involved in the
upregulation of the BK-binding and SP-binding sites on the
contralateral side. One possibility is that the process of
disease was spreading to the contralateral side and
thereby stimulated receptor upregulation in contralateral
DRGs. Indeed, during unilateral inflammation, cellular infil-
tration [74], SP and calcitonin gene-related peptide upreg-
ulation [55], an increase in the interleukin-6 content [75], a
loss of proteoglycans [10] and altered load-bearing [76]
have been observed on the contralateral side. However,
during AIA the contralateral knee did not show gross
inflammatory alterations; it is therefore questionable
whether the enhanced receptor expression in the contralat-
eral DRGs was due to the spreading of the inflammatory
disease to the contralateral side.
Because the upregulation was symmetrical and segmental,
it is also possible that the upregulation was caused by the
symmetrical innervation. In general, bilateral changes in the
nervous system after unilateral pathologies such as nerve
lesions and inflammation are not uncommon, although they
are not always observed [77,78]. Symmetrical efferent
effects on the tissue and/or the DRGs can be provided by
the sympathetic nervous system [79,80] or by the primary
afferent fibres in which dorsal root reflexes are generated.
Dorsal root reflexes are action potentials that originate in the
spinal cord entry zone of the afferent fibres and propagate
from there to the periphery [81–83]. Both of these neuronal
pathways depend on activity in the spinal cord; it has been
shown that the development of joint inflammation can be
attenuated by the spinal application of glutamate receptor
antagonists that reduce the activity of the spinal cord
neurons [84, 85]. The involvement of the central nervous
system in the generation of bilateral inflammation [86] and
bilateral degeneration of articular cartilage [87] has been
shown; it is therefore conceivable that efferent activity from
the central nervous system to the periphery might also influ-
ence the expression of receptors in DRG neurons.
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